Bamco Inc. NY Cuts Holdings in Repligen Co. (NASDAQ:RGEN)

Bamco Inc. NY lessened its stake in Repligen Co. (NASDAQ:RGEN) by 3.2% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 167,019 shares of the biotechnology company’s stock after selling 5,495 shares during the quarter. Bamco Inc. NY’s holdings in Repligen were worth $24,856,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Andra AP fonden purchased a new position in Repligen in the second quarter worth approximately $25,000. International Assets Investment Management LLC purchased a new stake in shares of Repligen during the 2nd quarter worth $33,000. UMB Bank n.a. grew its stake in shares of Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares in the last quarter. Lazard Asset Management LLC increased its holdings in Repligen by 206.1% in the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 136 shares during the last quarter. Finally, Blue Trust Inc. raised its stake in Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 127 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Stock Down 0.1 %

RGEN opened at $150.46 on Tuesday. The business has a 50 day moving average price of $141.18 and a two-hundred day moving average price of $142.27. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $211.13. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The firm had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. Repligen’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period last year, the firm posted $0.23 EPS. On average, equities research analysts predict that Repligen Co. will post 1.52 EPS for the current fiscal year.

Insider Transactions at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. The trade was a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on RGEN shares. Benchmark reiterated a “hold” rating on shares of Repligen in a report on Monday, August 5th. Wells Fargo & Company began coverage on shares of Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price target on the stock. Royal Bank of Canada restated an “outperform” rating and set a $205.00 price objective on shares of Repligen in a research report on Thursday, September 26th. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, November 22nd. Finally, Wolfe Research started coverage on shares of Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating for the company. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $190.25.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.